
http://dx.doi.org/10.1371/journal.pone.0068099

Published version (with publisher's formatting)

Available from Middlesex University's Research Repository at http://eprints.mdx.ac.uk/12096/

Copyright:

Middlesex University Research Repository makes the University's research available electronically.

Copyright and moral rights to this thesis/research project are retained by the author and/or other copyright owners. The work is supplied on the understanding that any use for commercial gain is strictly forbidden. A copy may be downloaded for personal, non-commercial, research or study without prior permission and without charge. Any use of the thesis/research project for private study or research must be properly acknowledged with reference to the work's full bibliographic details.

This thesis/research project may not be reproduced in any format or medium, or extensive quotations taken from it, or its content changed in any way, without first obtaining permission in writing from the copyright holder(s).

If you believe that any material held in the repository infringes copyright law, please contact the Repository Team at Middlesex University via the following email address:

eprints@mdx.ac.uk

The item will be removed from the repository while any claim is being investigated.
Enzymatic Formulation Capable of Degrading Scrapie Prion under Mild Digestion Conditions

Emeka A. Okoroma¹, Diane Purchase¹*, Hemda Garelick¹, Roger Morris², Michael H. Neale³*, Otto Windl³, Oduola O. Abiola⁴

¹ Department of Natural Sciences, School of Science and Technology, Middlesex University, London, United Kingdom, ² School of Biomedical Sciences, King’s College London, London, United Kingdom, ³ Animal Health and Veterinary Laboratories Agency (AHVLA), Surrey, United Kingdom, ⁴ PAP Rashidah Sa’adatul Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Gadong, Brunei Darussalam

Abstract

The prion agent is notoriously resistant to common proteases and conventional sterilisation procedures. The current methods known to destroy prion infectivity such as incineration, alkaline and thermal hydrolysis are harsh, destructive, environmentally polluting and potentially hazardous, thus limit their applications for decontamination of delicate medical and laboratory devices, remediation of prion contaminated environment and for processing animal by-products including specified risk materials and carcases. Therefore, an environmentally friendly, non-destructive enzymatic degradation approach is highly desirable. A feather-degrading Bacillus licheniformis N22 keratinase has been isolated which degraded scrapie prion to undetectable level of PrPSc signals as determined by Western Blot analysis. Prion infectivity was verified by ex vivo cell-based assay. An enzymatic formulation combining N22 keratinase and biosurfactant derived from Pseudomonas aeruginosa degraded PrPSc at 65°C in 10 min to undetectable level. A time-course degradation analysis carried out at 50°C over 2 h revealed the progressive attenuation of PrPSc intensity. Test of residual infectivity by standard cell culture assay confirmed that the enzymatic formulation reduced PrPSc infectivity to undetectable levels as compared to cells challenged with untreated standard scrapie sheep prion (SSBP/1) (p-value = 0.008 at 95% confidence interval). This novel enzymatic formulation has significant potential application for prion decontamination in various environmentally friendly systems under mild treatment conditions.

Introduction

Transmissible Spongiform Encephalopathies (TSEs) or prion diseases such as Creutzfeldt-Jakob disease (CJD) in humans, Bovine Spongiform Encephalopathy (BSE) in cattle, Chronic Wasting Disease (CWD) in mule deer and elk and scrapie in sheep and goat are a group of closely related, progressive, incurable and invariably fatal neurodegenerative disorders that affect the central nervous system (CNS) of mammals [1], [2].

The TSE agent is resistant to common proteases and withstands conventional physical and chemical sterilisation, inactivation and decontamination procedures [3-6].

Common prion decontamination methods include porous load autoclaving at 134°C for 18 min and immersing contaminated material in 1 M NaOH and/or 20,000 ppm NaOCl for 1 h at 20°C [1], [7]. However, these methods result in irreversible damage to medical devices [8], and may be ineffective in destroying prion infectivity [5], [6], [9].

Incineration [10], [11], thermal hydrolysis [12] and alkaline hydrolysis [13-15] destroy prions effectively. While incineration is suitable for destruction of prion in non-recoverable materials, it is impractical for the decontamination of recoverable and reusable materials (e.g. animal by-products), delicate medical and laboratory instruments, and contaminated environment [16]. Residual infectivity has also been reported after incineration of scrapie contaminated tissue [17-19]. In addition, environmental impact concerns, regulatory requirements and cost of such facility are limiting factors. Alkaline hydrolysis is unsuitable for application in the rendering of recoverable Specific Risk Materials (SRM) and carcases of prion infected tissue as it could result in end products that are extremely degraded and contain high concentration of salt residue, therefore diminishing its commercial value [20].

Enzymatic (microbial) degradation of prions has been explored for the obvious advantages that it is potentially able to destroy prion infectivity without destroying the decontaminated material. It is also the most practicable approach for remediation of prion contaminated environment without adversely affecting the environmental biota and/or ecology [21-23].

Since the earliest report of enzymatic degradation of scrapie prion [20], there have been several studies investigating prion decontamination [22], [27-33]. In most cases, the prion substrate was rendered proteolytically susceptible by either pre-heating at high temperature, digesting in the presence of chemical surfactants/detergents, denaturants and oxidising agents, incubating
under high alkaline conditions and digesting for an extended period of time or a combination of these approaches. The importance of detergents in the enzymatic degradation mechanism, such as in solubilising the prion substrate, has been particularly highlighted [22], [29], [30].

In general, the established methods of enzymatic degradation are harsh, environmentally and economically unsustainable, and may require a sequential multi-step approach that is complex and impractical for commercial application. Therefore, a simple, effective and efficient enzymatic degradation method that combines moderate pH and temperature conditions, relatively short digestion time and biological surfactant (biosurfactant) is highly desirable.

Biosurfactants are extracellular or membrane-associated amphiphilic surface-active biomolecules derived from biological sources [34], [35]. Pseudomonas aeruginosa is one of the prolific producers of biosurfactants [36], [37]. Biosurfactants are composed of a hydrophilic (head) and hydrophobic (tail) moieties [38], [39]. The hydrophilic moiety is usually a carbohydrate, amino acid, phosphate, cyclic peptide, carboxylic acid, or alcohol and the hydrophobic moiety is mostly a long-chain fatty acid, or fatty acid derivatives such as hydroxyl fatty acid or \( \alpha \)-alkyl-\( \beta \)-hydroxy fatty acid.

Biosurfactants have various applications in the petroleum industry [38], [40], environmental bioremediation [41-43], agricultural biocontrol [44-46] and in cosmetic, pharmaceutical and therapeutic products industry [35], [39], [47].

This paper reports the degradation of scrapie prion under mild digestion conditions by a novel enzymatic formulation which comprises keratinase and biosurfactant isolated from bacterial sources.

Materials and Methods

Materials

**Brain homogenate.** Harvested whole brain was homogenized in PBS into 10% (w/v) brain homogenate and stored at \(-80^\circ\)C. Subsequently, 1% (w/v) brain homogenate was prepared in sterile phosphate-buffered saline (PBS) to be used for digestion experiments. ME7 brain homogenate (kindly provided by Drs Stephen Whatley and Oduola Abiola of Neuroscience Department, KCL Institute of Psychiatry, London), SSBP/1 sheep scrapie homogenate (kindly provided by the biological archive Animal Health and Veterinary Laboratories Agency, UK) were used as scrapie brain homogenate materials, and normal brain homogenate was derived from C57BL/6 mice.

ME7 brain homogenate was produced under the UK Home Office Project Licence: ‘Host genetics of prion disease transmission’ and approved by King’s College London Ethical Review Process Committee (Denmark Hill Campus). Brain homogenate from C57BL/6 mice was covered by the licence PPL/70/6760: ‘How cells and tissues produce and respond to neurodegenerative amyloid’ and approved by King’s College London Ethical Review Process Committee (Guy’s Campus). The SSBP/1 material was produced under the Home Office Project Licence no. 70/5780 and was approved by the AHVLA Ethical Review Committee. All work fully met the requirements of the UK Animals (Scientific Procedures) Act 1986. All infectious scrapie material was handled according to the World Health Organisations infectious control guideline for transmissible spongiform encephalopathies [1].

**Cell line and culture medium.** SSBP/1-susceptible RK13\textsuperscript{VRQ,LP} cells were engineered to constitutively express ovine VRQ PrP allele; RK13 was transfected with a vector containing the ovine VRQ PrP gene under the control of the CMV promoter. The vector was described in a paper by Piening et al. [48]. RK13\textsuperscript{VRQ,GP} cells have similar level of sensitivity as Rov9 cells [49] to SSBP/1 infection (Neale, unpublished data) and were used in the standard scrapie cell assay (SSCA). The cells were maintained in Eagle’s minimal essential medium (EMEM, Gibco) supplemented with 10% fetal calf serum and 2% HEPES. RK13\textsuperscript{VRQ,GP} infection was cultured in OptiMEM medium (Invitrogen) supplemented with 10% foetal calf serum (Gibco) and antibiotics/antimyotic (Penicillin, 100 units; Streptomycin, 100 \( \mu \)g and Amphotericin B, 0.25 \( \mu \)g, Invitrogen).

**Proteases and biosurfactant.** Bacillus licheniformis N22 keratinase (EF) and Pseudomonas aeruginosa NCIMB 8626 biosurfactant (BS) were isolated as previously described [50] and [51] respectively. An enzymatic formulation (EF+BS) composed of keratinase and biosurfactant was prepared in the laboratory at Middlesex University. Proteinase K (PK) was bought from Fisher scientific, UK.

**Assay antibodies.** SAF83 (SPI-Bio, France) and Sha31 (Bertin Pharma) were used as primary antibodies to detect PrP signal in the Western Blot analysis. The secondary antibodies used were the Amersham ECL sheep anti-mouse IgG Horseradish peroxidase linked whole antibody (GE Healthcare, UK) and goat anti-mouse alkaline phosphatase conjugate (Sigma, UK).

Methods

**Digestion of brain homogenate substrates.** 10 \( \mu \)l of 1% scrapie-infected brain homogenates (IBH) was digested with PK (1 \( \mu \)l), EF (1 \( \mu \)l), BS (1 \( \mu \)l) or EF+BS at pH 7, digestion times (ranging from 10 min to 2 h) at 50°C or 65°C as specified for each experiment. Time-course digestion with EF+BS was carried out for 30, 45, 60, 90 and 120 min at 50°C, and for 10, 30 and 45 min at 65°C. EF (0.05, 0.1 and 0.4 \( \mu \)g/ml), BS (75 \( \mu \)g/ml) and PK (10, 50 and 100 \( \mu \)g/ml) final concentrations were investigated to determine their optimum concentrations. PK-digested and undigested IBH were used as the positive and the negative controls respectively. Digestion reaction was stopped with 1 \( \mu \)l of 50 mM Phenyl methyl sulfonyl fluoride (PMSF). All digestions were carried out in triplicates.

**Western Blot Analysis.** Digested samples were mixed with 2× sample buffer (11 \( \mu \)l) and heated for 10 min at 100°C on a dry

![Figure 1. Western blot profile of ME7 brain homogenate digested with EF with and without BS. Lanes 2, 3, 4, and 5 are ME7 scrapie brain homogenate digested at 65°C for 1 h with PK (100 \( \mu \)g/ml), EF+BS, BS and EF respectively. Total removal of PrP\textsuperscript{Sc} signal was achieved with EF+BS only. PrP\textsuperscript{Sc} was probed with SAF83 mAb.](https://www.plosone.org/fig1)
Scrapie Prion Degradation by Enzymatic Treatment

Figure 2. Time-course profile of ME7 brain homogenate digested with EF+BS at 50°C. Lane 1 is neat ME7 brain homogenate (positive control) and lane 2 is proteinase K treated sample (77 μg/ml final PK conc.). Lanes 3–7 are digested with EF+BS at 30–120 min respectively. Samples were digested at 50°C and PrPSc was probed with SAF83 mAb.
doi:10.1371/journal.pone.0068099.g002

Scrapie Cell Assay
To confirm the efficacy of the enzymatic formulation (EF+BS) to completely eliminate prion infectivity, SSBP/1 susceptible RK13VRQ.G9 cells were challenged with enzyme-digested SSBP/1 scrapie and analysed for residual infectivity.

Prion infectivity study confirmed that RK13VRQ.G9 cells propagated SSBP/1 scrapie prion but RK13VRQ.G9 cells inoculated with EF and EF+BS digested SSBP/1 scrapie did not propagate infectivity as shown by the absence of infected cells (detectable spots in the ELISPOT assay: Fig. 5). The number of infected cells per 5000 cells (cell number confirmed by trypan blue count) in the treatment groups compared to the incubated IBH group (both = 0.009, Two-Sample T-Test; Fig. 6). Although, a significantly lower number of cells were infected in the BS treatment group compared to the incubated IBH group (p = 0.033, Two-Sample T-Test; Fig. 6), the results show that cells inoculated with BS-treated brain homogenate sample remained infectious and were able to propagate infection in RK13VRQ.G9 cells. It was

Figure 3. Time-course profile of ME7 brain homogenate digested with EF+BS at 65°C. Lane 1 is neat ME7 brain homogenate (positive control) and lane 2 is proteinase K digested sample (77 μg/ml final PK conc.). Lanes 3–6 are digested with EF+BS at 10, 30, 45 and 60 min. Samples were digested at 65°C and PrPSc was probed with SAF83 mAb.
doi:10.1371/journal.pone.0068099.g003

Results
In vitro Degradation of ME7 Scrapie
ME7 scrapie brain homogenate (10 μl) digested with the enzymatic formulation (EF+BS) at 65°C for 1 h resulted in undetectable level of PrPSc as determined by Western Blot analysis (Fig. 1; Lane 3). Under these conditions, keratinase (EF) alone was unable to completely degrade ME7 scrapie, resulting in the typical PrPSc glycosylation bands (Fig. 1; Lane 5). Biosurfactant (BS) alone showed no discernible activity towards PrPSc degradation (Fig. 1; Lane 6). Digestion with PK resulted in the typical PrPSc bands (Fig. 1; Lane 2).

Time-course degradation carried out at 50°C for 30, 45, 60, 90 and 120 min demonstrated the progressive loss of detectable PrPSc signal over time (Fig. 2). Further optimisation showed complete degradation of PrPSc down to undetectable levels in 10 min at 65°C (Fig. 3).

PK at final concentrations of 10, 50 and 100 μg/ml completely digested normal brain homogenate (NBH) to undetectable levels of PrP (Fig. 4; lanes: 2–4) but did not digest ME7 infectious brain homogenate (IBH) beyond the expected reduction in size due to removal of the N-terminal domain (Fig. 4; lanes: 6–8). Digestion with the enzymatic formulation (EF+BS) at final concentrations of EF (0.05, 0.1 and 0.4 μg/ml) and BS (75 μg/ml rhamnose equivalent) resulted in complete or nearly complete loss of PrPSc signal in order of increasing dilution (Fig. 4).

Statistical analysis. Test of difference in the number of infected cells in the treatment groups were compared using Two-Sample T-Test.
also noted that SSBP/1 infectivity was significantly reduced by incubation at 65°C compared to IBH that was not exposed to heating (p = 0.044, Two-Sample T-Test; Fig. 6).

**Figure 4. Digestion of normal and ME7 brain homogenates with different concentrations of PK and EF.** Normal (NBH) and infected (IBH) brain homogenates digested at 65°C for 1 h with 10, 50 and 100 μg/ml of proteinase K (lanes 2, 3, 4 and lanes 6, 7, 8 respectively) and EF+BS formulation [1:50, 1:100 and 1:200 dilutions or 0.4, 0.1 and 0.05 μg/ml of EF and 75 μg/ml rhamnose equivalent (BS)] (lanes 9, 10, 11, 12) probed with SAF83 monoclonal antibody. Lanes 1 and 5 are undigested NBH and IBH controls, respectively.

doi:10.1371/journal.pone.0068099.g004

**Figure 5. Representative photograph of ELISPOT plate.** The wells contained infected RK13VRQ.G9 cells inoculated with IBH (SSBP/1), incubated IBH (heat treated SSBP/1) and BS (Biosurfactant digested SSBP/1). Wells inoculated with SSBP/1 digested with EF and EF+BS were completely devoid of infected cells. PrPSc was probed with sha31 mAb.

doi:10.1371/journal.pone.0068099.g005

**Discussion**

**Degradation of ME7 Scrapie Prion**

The enzymatic formulation (EF+BS) partially degraded ME7 scrapie prion at 50°C in 1 h but when the temperature was raised...
The enzymatic degradation method described in this study degraded scrapie prion under moderate physical condition (pH 7 and 65°C) and digestion time (10 min). In addition, it did not require a truncated multi-step approach (e.g., [22], [29], [45]) in which the infectious material is either pre-treated and/or digested with multiple enzymes or in the presence of chemical surfactants or alkali carrier such as NaOH. This enzymatic degradation method promises to be efficient and practical, and the constituent agents (N22 keratinase and biosurfactant) are purely biological agents of potential low production cost. Thus, this method could provide a good, environmentally friendly, more economically viable and safe alternative to existing prion decontamination methods.

Further work will include the decontamination of steel and soil-bound prion with this enzymatic preparation.

**Potential Applications of this Enzymatic Treatment Method**

Hitherto, the inability to achieve efficient prion degradation at mild digestion conditions (neutral pH, moderate temperature, and low enzyme concentration) limits the use of enzymatic decontamination in economic and operational terms. Therefore, enzymatic degradation at mild digestion conditions is of general interest in the decontamination of sensitive medical devices, animal products [Meat and Bone Meal (MBM) and SRM] and prion contaminated environment.

The inability of the enzyme-digested scrapie substrate to propagate infectivity in the susceptible RK13 VQRQ67 cells suggests the complete loss of SSBP/1 infectivity. Therefore, the efficacy of this enzymatic formulation for complete destruction of prion infectivity has been validated by the SSCA. This result suggests that the loss of detectable levels of PrPSc signal in the enzyme-digested scrapie prion as determined by Western blot correlated with loss of prion infectivity as determined by the SSCA. The complete destruction of the infectivity of field isolate of sheep scrapie (SSPB/1) is particularly very important in terms of disposal of sheep scrapie.

**Standard Scrapie Cell Assay (SSCA)**

Although Western blot analysis is a commonly used biochemical method for prion immunodetection, the presence of prion infectivity in samples with the apparent lack of detectable levels of PrPSc [59-61] limits its use for evaluating residual prion infectivity. A more consistent, reliable and sensitive method such as the SSCA was required to confirm results from Western blot analysis and to validate the efficacy of the enzymatic formulation for prion degradation.

SSCA was carried out to establish if the absence of PrPSc detection in the Western blot profile of the enzyme-digested SSBP/1 was accompanied by corresponding loss in prion infectivity. The result of the SSCA confirmed that the enzymatic formulation efficiently destroyed prion infectivity as shown by the inability of the enzyme-digested SSBP/1 brain homogenate to infect susceptible RK13 VQRQ67 cells (Figs 5 and 6). While EF also destroyed SSBP/1 infectivity, BS resulted in a significant reduction in the number of infected cells which suggests that SSBP/1 infectivity was significantly attenuated at the digestion temperature (65°C) but not enough to prevent infection of cells. The number of spot counts detected in the EF and enzymatic formulation treatment groups were probably background noise as confirmed by absence of visually detectable infected cells on the photographic image of the ELISPOT plate (Fig. 5).
Use of Biosurfactant in Prion Degradation

Chemical surfactants/detergents enhance enzymatic prion degradation [22], [26], [29], [31], [62], [63]. However, biosurfactants are particularly useful and advantageous because of their environmentally friendly properties (e.g. low toxicity, high biodegradability) and their biochemical properties enabling lowering of surface tension, increasing substrate surface area, substrate solubilisation and protein unfolding [32], [64]. In addition, biosurfactants inhibit pathogen adhesion and formation of biofilms on steel surfaces [35], [46], presenting a two fold advantage for decontamination of steel surfaces such as medical devices. Using biosurfactant would also prevent undesirable chemical load in the enzymatic degradation processes, and the need for additional facilities for effluent treatment.

This is the first report on the use of biosurfactant in the degradation of prion. In this study, crude biosurfactant was used resulting in substantial saving in cost and labour associated with biosurfactant purification.

Conclusion

A novel enzymatic formulation combining keratinase and biosurfactant in a remarkable synergy which efficiently degraded scrapie prion and destroyed its infectivity has been reported. This system has great potential for use in the environmentally friendly prion decontamination processes of surgical instruments and recoverable materials in general.

Acknowledgments

We thank Manika Choudhury (Middlesex University London), Angela Jen, Laurent Bournier (King’s College London) and Linda Davis (Animal Health and Veterinary Laboratories Agency, Surrey, UK) for their technical assistance.

Author Contributions

Conceived and designed the experiments: EO HG RM MN OW OA. Performed the experiments: EO MN. Analyzed the data: EO HG RM MN OW OA. Contributed reagents/materials/analysis tools: RM OW. Wrote the paper: EO HG RM MN OW OA.

References

Scrapie Prion Degradation by Enzymatic Treatment

46. Brzozowski B, Bednarski W, Golek P (2011) The adhesive capability of two *Lactobacillus* strains and physiochemical properties of their synthesised biosurfac-